TAXUS V: De Novo Lesion: A Randomized, Double-Blind Trial to Assess TAXUS Paclitaxel-Eluting Coronary Stents, SR Formulation, in the Treatment of De Novo Coronary Lesions

Trial Profile

TAXUS V: De Novo Lesion: A Randomized, Double-Blind Trial to Assess TAXUS Paclitaxel-Eluting Coronary Stents, SR Formulation, in the Treatment of De Novo Coronary Lesions

Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 Feb 2010

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms TAXUS-V
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 09 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Sep 2009 Results presented at the 21st Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
    • 25 Sep 2008 FDA approval received for TAXUS stent.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top